Moleculin Biotech to Present at the Q2 Virtual Investor Summit
Moleculin Biotech, Inc. (Nasdaq: MBRX), a clinical stage pharmaceutical firm, announced its participation in the Q2 Virtual Investor Summit on May 17, 2021, at 12:30 PM ET. CEO Walter Klemp will present, with management available for one-on-one meetings with investors. The conference aims to highlight Moleculin's innovative drug candidates that target resistant tumors and viruses. A live video webcast will be available on the company's Investor Relations page and archived for 90 days. For details, visit www.moleculin.com.
- None.
- None.
HOUSTON, May 11, 2021 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced that Walter Klemp, President and Chief Executive Officer of Moleculin, will present at the Q2 Virtual Investor Summit on Monday, May 17th at 12:30 PM ET.
In addition to the presentation, management will be available to participate in virtual one-on-one meetings with qualified members of the investor community who are registered to attend the conference. For more information about the conference, please visit the conference website.
A live video webcast will be accessible on the Events page in the Investors section of the Company's website (www.moleculin.com) and archived for 90 days following the event.
About Moleculin Biotech, Inc.
Moleculin Biotech, Inc. is a clinical stage pharmaceutical company focused on the development of a broad portfolio of oncology drug candidates for the treatment of highly resistant tumors and viruses. The Company's clinical stage drugs are: Annamycin, a next-generation anthracycline, designed to avoid multidrug resistance mechanisms with little to no cardiotoxicity being studied for the treatment of relapsed or refractory acute myeloid leukemia, more commonly referred to as AML, WP1066, an Immune/Transcription Modulator capable of inhibiting p-STAT3 and other oncogenic transcription factors while also stimulating a natural immune response, targeting brain tumors, pancreatic cancer and hematologic malignancies, and WP1220, an analog to WP1066, for the topical treatment of cutaneous T-cell lymphoma. Moleculin is also engaged in preclinical development of additional drug candidates, including other Immune/Transcription Modulators, as well as WP1122 and related compounds capable of Metabolism/Glycosylation Inhibition.
For more information about the Company, please visit http://www.moleculin.com.
Investor Contact:
JTC Team, LLC
Jenene Thomas
(833) 475-8247
MBRX@jtcir.com
View original content to download multimedia:http://www.prnewswire.com/news-releases/moleculin-biotech-to-present-at-the-q2-virtual-investor-summit-301288084.html
SOURCE Moleculin Biotech, Inc.
FAQ
When is Moleculin Biotech presenting at the Q2 Virtual Investor Summit?
Who is the CEO of Moleculin Biotech?
What is Moleculin Biotech's focus?
Where can I watch the Moleculin Biotech presentation?
How long will the webcast of Moleculin Biotech's presentation be available?
